Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts
- PMID: 27223431
- PMCID: PMC5352046
- DOI: 10.18632/oncotarget.9497
Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts
Abstract
Zoledronic acid (ZA) is a biphosphonate used for osteoporosis treatment and also proved to be effective to reduce the pain induced by bone metastases when used as adjuvant therapy in solid cancers. However, it has been recently proposed that ZA could have direct anti-tumour effects, although the molecular mechanism is unknown. We herein unravel a novel anti-tumour activity of ZA in prostate cancer (PCa), by targeting the pro-tumorigenic properties of both stromal and immune cells. Particularly, we demonstrate that ZA impairs PCa-induced M2-macrophages polarization, reducing their pro-invasive effect on tumour cells and their pro-angiogenic features. Crucially, ZA administration reverts cancer associated fibroblasts (CAFs) activation by targeting the mevalonate pathway and RhoA geranyl-geranylation, thereby impairing smooth muscle actin-α fibers organization, a prerequisite of fibroblast activation. Moreover, ZA prevents the M2 macrophages-mediated activation of normal fibroblast, highlighting the broad efficacy of this drug on tumour microenvironment. These results are confirmed in a metastatic xenograft PCa mouse model in which ZA-induced stromal normalization impairs cancer-stromal cells crosstalk, resulting in a significant reduction of primary tumour growth and metastases. Overall these findings reinforce the efficacy of ZA as a potential therapeutic approach to reduce cancer aggressiveness, by abrogating the supportive role of tumour microenvironment.
Keywords: cancer-associated fibroblasts; macrophages; mevalonate pathway; prostate cancer; zoledronic acid.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5352046/bin/oncotarget-08-118-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5352046/bin/oncotarget-08-118-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5352046/bin/oncotarget-08-118-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5352046/bin/oncotarget-08-118-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5352046/bin/oncotarget-08-118-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5352046/bin/oncotarget-08-118-g006.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/5352046/bin/oncotarget-08-118-g007.gif)
Similar articles
-
Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.J Cell Mol Med. 2010 Dec;14(12):2803-15. doi: 10.1111/j.1582-4934.2009.00926.x. J Cell Mol Med. 2010. PMID: 19818098 Free PMC article.
-
Zoledronic acid modulates antitumoral responses of prostate cancer-tumor associated macrophages.Cancer Immunol Immunother. 2008 Oct;57(10):1451-9. doi: 10.1007/s00262-008-0482-9. Epub 2008 Feb 23. Cancer Immunol Immunother. 2008. PMID: 18297280 Free PMC article.
-
Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion.Oncotarget. 2013 Sep;4(9):1449-60. doi: 10.18632/oncotarget.1201. Oncotarget. 2013. PMID: 24036536 Free PMC article.
-
Tumour macrophages as potential targets of bisphosphonates.J Transl Med. 2011 Oct 17;9:177. doi: 10.1186/1479-5876-9-177. J Transl Med. 2011. PMID: 22005011 Free PMC article. Review.
-
Diverse macrophages polarization in tumor microenvironment.Arch Pharm Res. 2016 Nov;39(11):1588-1596. doi: 10.1007/s12272-016-0820-y. Epub 2016 Aug 25. Arch Pharm Res. 2016. PMID: 27562774 Review.
Cited by
-
Exploring the role of the immune microenvironment in hepatocellular carcinoma: Implications for immunotherapy and drug resistance.Elife. 2024 Aug 15;13:e95009. doi: 10.7554/eLife.95009. Elife. 2024. PMID: 39146202 Free PMC article. Review.
-
Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer.Prostate Cancer Prostatic Dis. 2024 Apr 2. doi: 10.1038/s41391-024-00825-z. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 38565910 Review.
-
Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma.Cancer Immunol Immunother. 2024 Mar 2;73(4):62. doi: 10.1007/s00262-024-03652-2. Cancer Immunol Immunother. 2024. PMID: 38430249 Free PMC article.
-
Therapeutic strategies for gastric cancer targeting immune cells: Future directions.Front Immunol. 2022 Sep 23;13:992762. doi: 10.3389/fimmu.2022.992762. eCollection 2022. Front Immunol. 2022. PMID: 36225938 Free PMC article. Review.
-
Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.Med Oncol. 2022 Sep 29;39(12):239. doi: 10.1007/s12032-022-01842-5. Med Oncol. 2022. PMID: 36175691 Review.
References
-
- Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012;31:195–208. - PubMed
-
- Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010;70:6945–6956. - PubMed
-
- Giannoni E, Bianchini F, Calorini L, Chiarugi P. Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal. 2011;14:2361–2371. - PubMed
-
- Wan L, Pantel K, Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med. 2013;19:1450–1464. - PubMed
-
- Giannoni E, Taddei ML, Parri M, Bianchini F, Santosuosso M, Grifantini R, Fibbi G, Mazzanti B, Calorini L, Chiarugi P. EphA2-mediated mesenchymal-amoeboid transition induced by endothelial progenitor cells enhances metastatic spread due to cancer-associated fibroblasts. J Mol Med (Berl) 2013;91:103–115. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical